search
Back to results

Lithium and Acetate for Canavan Disease

Primary Purpose

Canavan Disease, Infantile, Deficiency Disease

Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Canavan Disease focused on measuring Leukodystrophy, Canavan disease,, Aspartoacylase,, Lithium,, Glyceryl Triacetate

Eligibility Criteria

1 Year - 15 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical and biochemical diagnosis of Canavan disease

Exclusion Criteria:

  • Renal disease
  • Thyroid disease
  • Cardiac disease
  • Impossibility to perform brain MRI

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    1

    Arm Description

    Outcomes

    Primary Outcome Measures

    The primary outcome will be a decrease of the NAA peak (> 20%) or the appearance of an acetate peak at the end of the treatment (10 months), using spectroscopy-MRI.

    Secondary Outcome Measures

    Secondary outcomes will be assessed at 10 months (end of the treatment): -Improvement of neuromotor performances (GMFM and Mullen scales), spasticity, and neurological severity
    -Improvement of epilepsy (number of seizures)
    -Decrease in NAA and increase in acetate contents in fluids (CSF, plasma, urine).

    Full Information

    First Posted
    April 9, 2008
    Last Updated
    April 20, 2015
    Sponsor
    Assistance Publique - Hôpitaux de Paris
    Collaborators
    European Leukodystrophy Association
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00657748
    Brief Title
    Lithium and Acetate for Canavan Disease
    Official Title
    Evaluation of the Tolerance and Efficiency of a Combined Oral Therapy With Lithium and GTA in Patients With Canavan Disease
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2015
    Overall Recruitment Status
    Withdrawn
    Study Start Date
    September 2009 (undefined)
    Primary Completion Date
    September 2010 (Actual)
    Study Completion Date
    January 2011 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Assistance Publique - Hôpitaux de Paris
    Collaborators
    European Leukodystrophy Association

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The aim of this study is to determine whether oral supplementation with lithium and acetate may improve the biological and clinical prognosis in patients with Canavan Disease.
    Detailed Description
    Canavan Disease is an autosomal recessive devastating demyelinating disease caused by a deficiency in Aspartoacylase (ASPA) enzyme. There is no available treatment. ASPA deficiency leads to:- the accumulation of high levels of N-acetylaspartate (NAA), involved in myelin degeneration and epilepsy;- the deficient synthesis of acetate in oligodendrocytes, that could impair CNS myelination.Lithium administration induces a decrease in NAA in the brain of the tremor rats (animal model for CD) and in one patient (JANSON, 2005). On the other hand, administration of acetate could improve myelination in Canavan patients.For this reason, we propose to combine both treatments: Lithium Gluconate and Glyceryl Triacetate (GTA). Eighteen patients, aged 1 to 15 years, will receive oral GTA or Lithium during 4 months, then both treatment in association during 6 months. Patients will be sequentially evaluated up to the end of the treatment and 2 months thereafter for:-tolerance of the therapy (careful monitoring of clinical and biological parameters).- efficacy of the therapy on clinical, biological and radiological parameters. Particularly, we will evaluate using MRI-spectroscopy and CSF samples the decrease in NAA and increase in acetate levels in the brain.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Canavan Disease, Infantile, Deficiency Disease, Aspartoacylase, Leukodystrophy, Spongiform
    Keywords
    Leukodystrophy, Canavan disease,, Aspartoacylase,, Lithium,, Glyceryl Triacetate

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    1
    Arm Type
    Experimental
    Intervention Type
    Drug
    Intervention Name(s)
    Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)
    Other Intervention Name(s)
    Lithium Gluconate (drug), Glyceryl Triacetate, GTA (drug)
    Intervention Description
    Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study
    Primary Outcome Measure Information:
    Title
    The primary outcome will be a decrease of the NAA peak (> 20%) or the appearance of an acetate peak at the end of the treatment (10 months), using spectroscopy-MRI.
    Time Frame
    10 months
    Secondary Outcome Measure Information:
    Title
    Secondary outcomes will be assessed at 10 months (end of the treatment): -Improvement of neuromotor performances (GMFM and Mullen scales), spasticity, and neurological severity
    Time Frame
    10 months
    Title
    -Improvement of epilepsy (number of seizures)
    Time Frame
    10 months
    Title
    -Decrease in NAA and increase in acetate contents in fluids (CSF, plasma, urine).
    Time Frame
    10 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    1 Year
    Maximum Age & Unit of Time
    15 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Clinical and biochemical diagnosis of Canavan disease Exclusion Criteria: Renal disease Thyroid disease Cardiac disease Impossibility to perform brain MRI
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Patrick Aubourg, MD, PhD
    Organizational Affiliation
    Assistance Publique - Hôpitaux de Paris
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Caroline Sevin, MD, PhD
    Organizational Affiliation
    Assistance Publique - Hôpitaux de Paris
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    16002461
    Citation
    Mathew R, Arun P, Madhavarao CN, Moffett JR, Namboodiri MA. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain. J Pharmacol Exp Ther. 2005 Oct;315(1):297-303. doi: 10.1124/jpet.105.087536. Epub 2005 Jul 7.
    Results Reference
    result
    PubMed Identifier
    15784740
    Citation
    Madhavarao CN, Arun P, Moffett JR, Szucs S, Surendran S, Matalon R, Garbern J, Hristova D, Johnson A, Jiang W, Namboodiri MA. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5221-6. doi: 10.1073/pnas.0409184102. Epub 2005 Mar 22.
    Results Reference
    result
    PubMed Identifier
    16194720
    Citation
    Janson CG, Assadi M, Francis J, Bilaniuk L, Shera D, Leone P. Lithium citrate for Canavan disease. Pediatr Neurol. 2005 Oct;33(4):235-43. doi: 10.1016/j.pediatrneurol.2005.04.015.
    Results Reference
    result
    PubMed Identifier
    12064356
    Citation
    Baslow MH, Kitada K, Suckow RF, Hungund BL, Serikawa T. The effects of lithium chloride and other substances on levels of brain N-acetyl-L-aspartic acid in Canavan disease-like rats. Neurochem Res. 2002 May;27(5):403-6. doi: 10.1023/a:1015504031229.
    Results Reference
    result
    Links:
    URL
    http://www.ela-asso.com/
    Description
    ELA (European Leukodystrophy Association)

    Learn more about this trial

    Lithium and Acetate for Canavan Disease

    We'll reach out to this number within 24 hrs